Cargando…

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

BACKGROUND: Interferon-free regimens to treat hepatitis C virus (HCV) genotype 1 are effective but costly. At this time, payers in the United States use strategies to control costs including (1) limiting treatment to those with advanced disease and (2) negotiating price discounts in exchange for exc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linas, Benjamin P., Morgan, Jake R., Pho, Mai T., Leff, Jared A., Schackman, Bruce R., Horsburgh, C. Robert, Assoumou, Sabrina A., Salomon, Joshua A., Weinstein, Milton C., Freedberg, Kenneth A., Kim, Arthur Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414108/ https://www.ncbi.nlm.nih.gov/pubmed/28480259 http://dx.doi.org/10.1093/ofid/ofw266

Ejemplares similares

The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes
por: Linas, Benjamin P., et al.
Publicado: (2014)

Relationship Between Hepatitis C Clinical Testing Site and Linkage to Care
por: Assoumou, Sabrina A., et al.
Publicado: (2014)

Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa
por: Paltiel, A. David, et al.
Publicado: (2017)

Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County
por: Flash, Moses J E, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Probiotic Use to Prevent Clostridium difficile Infection in Hospitalized Adults Receiving Antibiotics
por: Shen, Nicole T, et al.
Publicado: (2017)

The Cost-effectiveness of a Point-of-Care Paper Transaminase Test for Monitoring Treatment of HIV/TB Co-Infected Persons
por: Rajasingham, Radha, et al.
Publicado: (2017)

Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis
por: Resch, Stephen C, et al.
Publicado: (2006)

Budget Impact of Medicaid Section 1115 Demonstrations for Early HIV Treatment
por: Schackman, Bruce R., et al.
Publicado: (2005)

The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets
por: Morgan, Jake R, et al.
Publicado: (2017)

Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus
por: Desmonde, Sophie, et al.
Publicado: (2019)

Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study
por: Aldridge, Arnie P., et al.
Publicado: (2020)

Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis
por: Turner, Hugo C., et al.
Publicado: (2017)

Cost-effectiveness of Routine Provider-Initiated Testing and Counseling for Children With Undiagnosed HIV in South Africa
por: Stanic, Tijana, et al.
Publicado: (2021)

Propensity-Matched Cost of Clostridioides difficile Infection Overdiagnosis
por: Madden, Gregory R, et al.
Publicado: (2020)

Improving Aztreonam Stewardship and Cost Through a Penicillin Allergy Testing Clinical Guideline
por: Chen, Justin R, et al.
Publicado: (2018)

Incidence and Costs of Clostridium difficile Infections in Canada
por: Levy, Adrian R., et al.
Publicado: (2015)

The Cost-Effectiveness of Tuberculosis Preventive Therapy for HIV-Infected Individuals in Southern India: A Trial-Based Analysis
por: Pho, Mai T., et al.
Publicado: (2012)

2570. HCV Screening Practices Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers in the United States
por: Epstein, Rachel L, et al.
Publicado: (2018)

Perceptions of Telemedicine and Costs Incurred by a Visit to a General Infectious Diseases Clinic: A Survey
por: Evers, Emily C, et al.
Publicado: (2022)

Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial
por: Kapadia, Shashi N, et al.
Publicado: (2022)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics
por: Adelman, Max W, et al.
Publicado: (2017)

Harmonizing healthcare and other resource measures for evaluating economic costs in substance use disorder research
por: Papp, Michelle A., et al.
Publicado: (2021)

Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
por: Savinkina, Alexandra, et al.
Publicado: (2022)

The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population
por: Ferrante, Nicole D, et al.
Publicado: (2022)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Cost of Herpes Zoster in Patients With Selected Immune-Compromised Conditions in the United States
por: Li, Qian, et al.
Publicado: (2016)

Use of Ceftriaxone and Benzylpenicillin in Outpatient Parenteral Antimicrobial Therapy: Spectrum vs Cost
por: Kalatharan, L, et al.
Publicado: (2023)

Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts
por: Neilan, Anne M., et al.
Publicado: (2020)

Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil
por: Carvalho, Janaína de Pina, et al.
Publicado: (2021)

The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011
por: Simmering, Jacob E., et al.
Publicado: (2017)

Public Health Impact and Cost-Effectiveness of Screening for Active Tuberculosis Disease or Infection Among Children in South Africa
por: Brough, Joseph, et al.
Publicado: (2023)

Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study
por: Barocas, Joshua A, et al.
Publicado: (2022)

Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts
por: Neilan, Anne M, et al.
Publicado: (2020)

Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States
por: Cowan, James F., et al.
Publicado: (2017)

Cost-effectiveness of Xpert(®)MTB/RIF in the diagnosis of tuberculosis: pragmatic study
por: da Silva, Suely Conceição Alves, et al.
Publicado: (2021)

Delayed Tuberculosis Treatment and Cost of Care in a Low-Incidence Country
por: O’Connell, James, et al.
Publicado: (2022)

Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2022)

Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
por: Losina, Elena, et al.
Publicado: (2009)

Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for People Experiencing Sheltered Homelessness During the COVID-19 Pandemic
por: Baggett, Travis P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_64r93npoihhgksaei6a087g88b